Liposomal NMN is sold on the same promise as every other liposomal supplement: wrap the molecule in a fat bubble and more of it survives your digestion. There is a problem with applying that pitch to NMN specifically, and it is not the one you would expect.
The problem is that plain NMN already absorbs, and published human trials established it years ago. The liposomal version is charging a premium to solve something the literature shows was never broken — which is a different situation from the ordinary oral precursors this product is priced above. The premium formats are also the dearest per gram of active, as the NMN ranking shows.
Regular NMN is already orally bioavailable
The first human safety study gave single oral doses of 100, 250 and 500 mg of NMN to 10 healthy men and tracked them for five hours. Plasma concentrations of two nicotinamide breakdown products rose significantly and dose-dependently — the authors’ evidence that the NMN was absorbed and metabolized rather than passing through[1].
Longer trials measured the endpoint that matters commercially. In a randomized, double-blind, placebo-controlled trial of 80 healthy middle-aged adults (n = 80) on 300, 600 or 900 mg of ordinary oral NMN daily, blood NAD rose significantly in every dose group at day 30 and day 60 against both placebo and baseline (all p ≤ 0.001), with a clear dose-response [2].
That is the bar a delivery technology has to beat, and it is already a high one. The honest question for a liposomal NMN product is not “does it get absorbed” but “does it get absorbed better than the cheap capsule that has been shown to work”. That is a comparison, and comparisons need a study.
What has actually been tested
We searched PubMed four ways on September 13, 2026, and the results are worth stating precisely rather than summarizing.
A search for liposomal NMN clinical trial returned zero results. A search for liposomal nicotinamide mononucleotide bioavailability human returned zero results. A search for liposomal nicotinamide mononucleotide oral absorption returned zero results. The broadest search, liposomal nicotinamide mononucleotide, returned 11 papers — every one of them preclinical work on delivery vehicles in cells, animals or laboratory models, and none of them a human trial of an oral liposomal NMN supplement. As a control, nicotinamide mononucleotide randomized controlled trial returned 32, so the instrument was working when the other three came back empty.
Two of those 11 come closest to the claim on a supplement label, and both are worth reading properly because they are not what the pitch implies.
The first developed elastic cationic liposomal nanogels as a platform for topical NMN delivery — something applied to skin, not swallowed. The authors report that NMN’s high hydrophilicity and poor skin permeability are what motivated the work, and their formulation achieved a penetration enhancement of 22.7% compared with free NMN on the laboratory bench [3]. Careful work, on a different route of administration, for a cosmetic purpose.
The second encapsulated NMN together with Matrigel in liposomal vesicles for sarcopenia, and tested them in vitro in a hydrogen-peroxide model of muscle cell damage, where the formulations reduced oxidative damage and preserved mitochondrial function[4]. A real result, in a dish, on a formulation nobody is selling you.
So does liposomal NMN work better?
Nobody has published the study that would answer that. There is no human pharmacokinetic trial comparing liposomal NMN against ordinary NMN and showing a larger or longer rise in blood NAD⁺ — which is the specific comparison the price premium is charging you for.
This is an absence of evidence rather than proof of failure, and we would rather say that plainly than pretend to a certainty nobody has earned. But the burden sits with the seller, and it is a lighter burden than usual here: the comparator already exists, the assay is routine, and the trial would be inexpensive. A company charging double for a delivery technology could run it in a quarter.
How this differs from liposomal NAD⁺
It is worth separating the two, because they are often sold from the same page and only one of them is answering a real question.
Liposomal NAD⁺ at least addresses a genuine obstacle: NAD⁺ itself is a large, charged molecule that is broken down in the gut rather than absorbed intact, which is the reason the entire research field went to precursors in the first place. That product is unproven, but it is unproven while attempting something hard.
Liposomal NMN is unproven while attempting something the plain capsule already does. If you want the fuller comparison of the two precursors themselves, NMN versus NR is the place to start, and what NAD⁺ actually is explains why the precursor route exists at all.
What we would do
Buy the form that has the trials, and compare what you pay for it per gram of actual NMN rather than per bottle. That gap is usually wider than the shelf price suggests, because the premium formats tend to put less active ingredient in a serving: among the brands we have checked, a liposomal NAD⁺ liquid runs $55.95 for 100 mg a serving, while a plain capsule of 300 mg nicotinamide riboside is $40.50 and a 300 mg NMN capsule is $19.95. Three times the material for a third of the price is not a rounding difference — our price comparison and cost calculator are built to surface exactly that.
If the liposomal claim is ever backed by a published head-to-head against plain NMN, we will update this page and say so. Until then, treat “enhanced absorption” on an NMN label as a claim about chemistry rather than a finding about people, and put the difference into the format with the evidence — an ordinary oral precursor.